GlobeStar Therapeutics Corporation
GSTC
$0.00
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -84.88% | 17.95% | 0.45% | -4.00% | 836.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -84.88% | 17.95% | 0.45% | -4.00% | 836.53% |
| Operating Income | 84.88% | -17.95% | -0.45% | 4.00% | -836.53% |
| Income Before Tax | 84.58% | -16.51% | 1.27% | -13.72% | -711.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.58% | -16.51% | 1.27% | -13.72% | -711.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.58% | -16.51% | 1.27% | -13.72% | -711.20% |
| EBIT | 84.88% | -17.95% | -0.45% | 4.00% | -836.53% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 86.67% | 0.00% | 0.00% | 0.00% | -650.00% |
| Normalized Basic EPS | 90.00% | 0.00% | 0.00% | 33.33% | -900.00% |
| EPS Diluted | 86.67% | 0.00% | 0.00% | 0.00% | -650.00% |
| Normalized Diluted EPS | 90.00% | 0.00% | 0.00% | 33.33% | -900.00% |
| Average Basic Shares Outstanding | 43.32% | 45.72% | 32.88% | 33.43% | 32.32% |
| Average Diluted Shares Outstanding | 43.32% | 45.72% | 32.88% | 33.43% | 32.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |